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Introduction
A meta-analysis involves taking data from more than one study
and analyzing it to derive a pooled estimate, commonly referred
to as a summary estimate. Meta-analyses can vary considerably
from very simple to very complex, and there is a variety of
different software packages available to aid the process. As with
any good research, the most important thing is asking the right
question. In the context of meta-analyses, my perspective is very
broad in that I believe it is relevant to pool as much data as
possible; i.e., for the most part, all apples are oranges and vice
versa, and the extensive data set can then be used to try to
explain any differences according to outcomes. The philosophy
behind this approach is that if we expect that a drug class is going
to provide a largely similar direction of effect across a broad
range of patients, pooling data from studies of different types of
drugs and different dosages of drugs is reasonable, and should
facilitate subsequent subgroup analyses; although, it is most
important to deﬁne the questions to be addressed a priori.
Consistency of Effects
The consistency of the direction of effect across trials is the ﬁrst
parameter to consider regarding pooling of data. Ideally, studies
examining interventions for a particular indication would all
demonstrate a similar estimate of the size of the effect and meta-
analysis would further corroborate this. However, as in reality
this doesn’t happen very often, a visual assessment of heteroge-
neity should be undertaken to decide whether or not meta-
analysis is likely to be useful, and to determine which data to
pool. To put it very simply, a meta-analysis of four studies, two
of which exhibit a positive effect and two of which exhibit a
harmful effect, is not going to be informative without some
understanding of why these studies have such disparate results.
In the “real world,” generally, some studies give positive results
while others give negative results, but the overall direction of the
effect tends to be relatively consistent (Fig. 1), and upon pooling
the data, additional analyses based on prior knowledge can be
pre-planned to help explore and explain the discrepancies.
Assumptions Prior to Pooling Data
A very narrow or very broad approach can be taken to pooling
data. In the latter approach, data may be pooled across a variety
of different interventions and a variety of patient populations,
which allows for extensive exploration of the data that may help
to identify causes of variability in outcomes, and facilitate treat-
ment comparisons. Causes in variability in outcomes across
studies can be assessed in a variety of ways. For example, sensi-
tivity analysis can be used to determine the impact of predeﬁned
parameters on the results of the meta-analysis. Taking statins for
the secondary prevention of cardiovascular events as an example,
studies primarily involving diabetic patients may be excluded
from the pooled dataset because they are a particularly high-risk
group that are expected to have worse outcomes than the general
study population. Data pooling may also be inﬂuenced by the
logistics for predeﬁned subgroup analyses of speciﬁc patient popu-
lations, interventions or outcomes. Various tests can be applied to
assess data heterogeneity, and to gauge the consistency of sub-
group analyses. The most common of these is the I-squared
statistic, a measure of the proportion of inconsistency of an
analysis that cannot be explained by chance. It ranges between 0%
and 100% with lower values representing less heterogeneity.
Meta-regression, a more sophisticated method for investigating
heterogeneity of effects across studies, examines the relationship
between one or more study parameters and the sizes of effect
observed in the studies; again, software is available to perform this
function.
Comprehensive Meta-Analysis—Statins
Two models commonly used in meta-analysis are the ﬁxed-effects
and random-effects models. The former makes the assumption
that the individual speciﬁc effect is correlated with the indepen-
dent variables; i.e., it assumes there is a single true value underly-
ing all study results. The latter assumes that the individual speciﬁc
effects are uncorrelated with the independent variables; by assum-
ing greater variability across studies, greater weight is placed on
smaller studies. In our hands, meta-analysis of data from 41
studies of the efﬁcacy of statins in cardiovascular disease, involv-
ingmore than 41,000 participants, led to an estimated relative risk
reduction of all-cause mortality of 0.85 (conﬁdence interval (CI);
0.81 to 0.90) with a ﬁxed-effects model, and 0.83 (CI; 0.78 to
0.90) with the more conservative random-effects model. In
general, because it is more conservative, the random-effects model
is favored by statisticians; however, there are instances when the
ﬁxed-effects approach is more reasonable. For example, some of
the statin trials included in the analysis had 10,000 participants,
while others had less than 100. In this case, it could be assumed
that the larger trials are of better quality than the smaller trials, so
a ﬁxed-effects model may therefore be more appropriate. Statins
have been extensively studied in clinical trials and it is generally
accepted that they are an effective drug class for the prevention of
cardiovascular events in patients at increased risk of cardiovascu-
lar disease, or those with established cardiovascular disease. Con-
sistent with this, both of our analytical models conﬁrmed that
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statins are indeed an effective intervention that signiﬁcantly
reduces all-cause mortality. Notably, however, upon examining
the data from the individual trials, it appears that in most cases,
statins do not have a statistically signiﬁcant effect on this endpoint
(Fig. 2). So, despite the fact that many of these trials included
thousands of participants, because of the relatively low number of
events, many were underpowered to demonstrate an intervention
effect of this nature.
Figure 1 Visual assessment of heterogeneity
(artiﬁcial data). CI, conﬁdence interval.
Figure 2 Effect of statins on all-cause mortality. CI, conﬁdence interval.
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Subgroup Analysis
A basic assumption in meta-analysis is that the event rates rela-
tive to the control group are expected to be similar across trials.
The absolute risk differences, on the other hand are less likely to
be consistent, because some trials involve individuals from very
high risk populations, while others consider only lower risk
populations. A number of rules exist to guide the valid parsing of
data by subgroup analysis, with the ﬁrst being that the questions
must be deﬁned a priori, so as to avoid observing apparently
signiﬁcant effects that have occurred by chance, the probability
of which increases with multiple analyses. Given the increasing
probability of ﬁnding a signiﬁcant result by chance, the subgroup
analyses should be one of only a small number of hypothesized
effects—a ball park number being one subgroup analysis per 10
trials. Another consideration in subgroup selection is whether the
subgroup is importantly different from other subgroups. Going
back to the example of statins, atorvastatin, and lovastatin have
relative risk reductions of all cause mortality of 0.78 and 0.82,
respectively. In this case, the question becomes whether or not
expert opinion considers this to be a particularly important dif-
ference in the context of the disease area. It is also important to
asses the consistency of the subgroup effect, and whether or not
there is a biological or social reason to support the subgroup
analysis; for example, a subanalysis by drug type may be reveal-
ing if the drugs have different mechanisms of action, or issues
with tolerability.
Statin Subgroup Analysis
Pooled estimates according to the individual subgroup of the
statins are shown in Table 1. Fluvastatin, pravastatin, and simv-
astatin were able to demonstrate a signiﬁcant effect in both ﬁxed-
and random-effect models. As indicated by the Tau2 and I2
statistics, atorvastatin and simvastatin were associated with vari-
ability across trials. However, because of the large number of
individuals randomized, simvastatin was still able to demonstrate
an effect in ﬁxed-effect analysis, although this was lost in the
random-effects model. It is worth noting that both atorvastatin
and pravastatin have a considerably larger number of patients
ever randomized to them, in a larger number of trials, than the
other drugs of the class. Thus, even though rosuvastatin was
unable to demonstrate a signiﬁcant effect (there were only two
trials included in the data set), it is most likely that because of the
low event rate observed for this endpoint, this subgroup analysis
is underpowered to show a signiﬁcant effect. Similarly, with
lovastatin, very few patients have been randomized to this drug.
In this case, the pooled estimate headed in the wrong direction,
but with very wide conﬁdence intervals; as such, it can not be
ruled out that lovastatin works well within one secondary popu-
lation, but may have a harmful effect in another.
Meta-analysis: The “Gold Standard”?
Over the last decade, the work of the Cochrane Collaboration
and others has exposed meta-analysis as an approach that can
help resolve questions of uncertainty about medical interventions
and disease effects, and it has acquired the reputation of being
somewhat of a “gold standard.” However, if we are to attain
deﬁnitive evidence, it is important that the meta-analysis itself is
appropriately powered. The recommendation for achieving the
appropriate power, also known as the optimal information size,
is that the meta-analysis is at least as well-powered, if not better
powered, than a good quality clinical trial. For meta-analyses,
the optimal information size can be calculated using the realistic
event rates that occurred in the clinical trials included in the
pooled sample, and the minimal effects of treatment that would
be considered to be of signiﬁcance to patient care. Incidentally, it
is worth noting here that the overestimation of event rates used
in power calculations to determine sample size for prospective
clinical trials is often the source of error that leads to their being
underpowered, and unable to conclusively demonstrate effects.
In our meta-analysis of the effects of statins, we found a very low
rate of all-cause mortality of only 10% among control groups
and 9.2% among intervention groups. As such, a clinical trial
would require a very large sample size in order to demonstrate a
signiﬁcant difference between these ﬁndings; indeed, based on
these numbers, 26,000 participants would have to be included in
the study. The broad sample size of 41,000 patients in our
meta-analysis permits us to make a strong inference on whether
or not statins as a drug class are effective in secondary prevention
of all-cause mortality; however, it is not particularly well-
powered to discriminate the effects of individual statins.
Closing Remarks
Meta-analysis provides a compelling approach to evaluating data
across many clinical trials. It offers the option of applying a very
broad pooling of data that provides sufﬁcient power to conclude
strong inferences, and facilitates investigations according to a
priori determined subgroups. However, of note, a degree of
knowledge of the patient population, the disease area and the
intervention outcome is required so as to maximize the utility of
the data through informed probing. As a ﬁnal note, the applica-
tion of the concept of optimal information size in meta-analyses
may well qualify their reputation as the “gold standard” in
clinical intervention research in the future.
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Table 1 Subgroup analysis of the efﬁcacy of statins in the prevention of
all-cause mortality
Statin Fixed Random Tau2 I2 (%)
Atorvastatin 0.85 (0.69–1.05) 0.77 (0.55–1.08) 0.17 16
Fluvastatin 0.68 (0.48–0.96) 0.68 (0.48–0.96) 0 0
Lovastatin 1.11 (0.32–3.86) 1.11 (0.32–3.86) 0 0
Pravastatin 0.81 (0.74–0.89) 0.81 (0.74–0.89) 0 0
Rosuvastatin 0.95 (0.87–1.03) 0.95 (0.87–1.03) 0 0
Simvastatin 0.71 (0.60–0.85) 0.70 (0.39–1.28) 0.18 39
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